Literature DB >> 18437119

Availability of cefixime 400 mg tablets--United States, April 2008.

.   

Abstract

The only current CDC-recommended options for treating Neisseria gonorrhoeae infections are from a single class of antibiotics, the cephalosporins. Within this class, ceftriaxone, available only as an injection, is the recommended treatment for all types of gonorrhea infections (i.e., urogenital, rectal, and pharyngeal). The only oral agent recommended currently by CDC for treatment of uncomplicated urogenital or rectal gonorrhea is a single dose of cefixime 400 mg. Availability of cefixime had been limited since July 2002, when Wyeth Pharmaceuticals (Collegeville, Pennsylvania) discontinued manufacturing cefixime tablets in the United States. Beginning in April 2008, cefixime (Suprax) 400 mg tablets are again available in the United States.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18437119

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  4 in total

1.  Strain typing and antimicrobial resistance of fluoroquinolone-resistant Neisseria gonorrhoeae causing a California infection outbreak.

Authors:  Sheldon R Morris; Douglas F Moore; Paul B Hannah; Susan A Wang; Julia Wolfe; David L Trees; Gail Bolan; Heidi M Bauer
Journal:  J Clin Microbiol       Date:  2009-07-22       Impact factor: 5.948

2.  Antimicrobial resistant gonorrhea in Atlanta: 1988-2006.

Authors:  Jodie Dionne-Odom; Pradnya Tambe; Eileen Yee; Hillard Weinstock; Carlos del Rio
Journal:  Sex Transm Dis       Date:  2011-08       Impact factor: 2.830

3.  Changes in fluoroquinolone use for gonorrhea following publication of revised treatment guidelines.

Authors:  Deborah Dowell; Lin H Tian; Jeffrey A Stover; Jennifer A Donnelly; Summer Martins; Emily J Erbelding; Raul Pino; Hillard Weinstock; Lori M Newman
Journal:  Am J Public Health       Date:  2011-11-28       Impact factor: 9.308

Review 4.  The use of cephalosporins for gonorrhea: the impending problem of resistance.

Authors:  Pennan M Barry; Jeffrey D Klausner
Journal:  Expert Opin Pharmacother       Date:  2009-03       Impact factor: 3.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.